TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02422862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-TSM
Description: Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization.
Study: NCT03944473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
Study: NCT04621773

Intervention type: PROCEDURE
Intervention: Preimplantation Genetic Screening(exposure)
Description: Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
Study: NCT01257425

Intervention type: DRUG
Group type: OTHER
Intervention: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Description: Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.

Intervention type: DRUG
Group type: OTHER
Intervention: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Description: Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.
Study: NCT00552487

Intervention type: DRUG
Group type: OTHER
Intervention: synacthen
Description: 1 µg synacthen in the vein

Intervention type: DRUG
Group type: OTHER
Intervention: synacthen
Description: 1 µg synacthen in the vein

Intervention type: DRUG
Group type: OTHER
Intervention: synacthen
Description: 1 µg synacthen in the vein

Intervention type: DRUG
Group type: OTHER
Intervention: synacthen
Description: 1 µg synacthen in the vein
Study: NCT05012891

Intervention type: OTHER
Intervention: OneStep Smartphone Application
Description: OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan.
Study: NCT03466801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MP and CTX
Description: Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
Study: NCT04633551

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory supplement
Description: commercially available combination of curcumin, quercitin, resveratrol, and green tea
Study: NCT04018599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MSB11022
Description: Single dose, as a solution, administered subcutaneously, using an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MSB11022
Description: Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
Study: NCT01822236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy Program
Description: The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One technique of craniosacral therapy
Description: Decompression L5-S1: lumbosacral decompression
Study: NCT03243877

Intervention type: OTHER
Intervention: MammoAlert Screening Test
Description: Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.

Intervention type: OTHER
Intervention: MammoAlert Screening Test
Description: Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
Study: NCT02388867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
Description: Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous vein bypass grafting
Description: Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
Study: NCT02870335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation
Description: Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
Study: NCT03948555

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)
Description: All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)
Description: All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
Study: NCT03087019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard use of radiation is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
Study: NCT01724853

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Resection suspension interposition arthroplasty or Arthrodesis

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative
Description: Injection
Study: NCT01666457

Intervention type: OTHER
Intervention: SOFFI
Description: NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
Study: NCT01209143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/ethinyl estradiol
Description: Norethindrone/ethinyl estradiol was supplied in tablets.
Study: NCT03536260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant with NanoBone graft
Description: Using of NanoBone graft to fill the gap in the socket after immediate implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant with Xenograft
Description: Using of Xenograft to fill the gap in the socket after immediate implant placement
Study: NCT02647567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine Intake
Description: The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intake
Description: The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
Study: NCT03829293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation group
Description: usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
Study: NCT00723021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zileuton
Description: 1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo tablets + placebo oral dispersion, single dose.
Study: NCT00398645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X 200mcg,GW685698X 200mcg and 400mcg
Study: NCT03068065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
Study: NCT03041519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopy ablation
Description: Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
Study: NCT00425802

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: anti-thymocyte globulin
Study: NCT05635981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
Study: NCT04115085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand therapy (18 treatments)
Description: 18 treatments (ea. 20 Min) within 9 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (18 treatments)
Description: 18 treatments (ea. 10 Min) within 9 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined hand therapy and therapeutic ultrasound (18 treatments)
Description: 18 treatments (ea. 30 Min) within 9 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound group (18 treatments)
Description: Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
Study: NCT01827293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Study: NCT03796260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Test Formulation (F1)
Description: Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Test Formulation (F1)
Description: Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Reference Formulation (F06)
Description: Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Reference Formulation (F06)
Description: Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
Study: NCT02667977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 Normal Saline
Description: Use of 0.9 Normal Saline for maintenance IV fluids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.45 Normal Saline
Description: Use of 0.45 Normal Saline for maintenance IV fluids
Study: NCT00320125

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice plus calcium
Description: \> 1,200mg Ca (four glasses of orange juice plus calcium)per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy products
Description: \> 1,200mg Ca (by consuming milk, yogurt, and cheese)
Study: NCT02764216

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective mucosal irradiaton
Description: Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
Study: NCT05341596

Intervention type: PROCEDURE
Intervention: repeat endotracheal intubation
Description: repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
Study: NCT02091453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APT training
Description: APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APT training
Description: APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiprofessional rehabilitation
Description: Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiprofessional rehabilitation
Description: Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
Study: NCT01523925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCIT
Description: This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCIT
Description: This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAT
Description: The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAT
Description: The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention group
Description: The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Study: NCT03748407

Intervention type: OTHER
Group type: OTHER
Intervention: Dosages of Thyroid parameters
Description: Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
Study: NCT03422588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
Study: NCT00414687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventavis (Iloprost, BAYQ6256)
Study: NCT03170154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon aspheric hydrophobic acrylic monofocal IOL
Description: Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
Study: NCT00905112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Receives manual therapy, stabilization exercise and patient education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard OB Care
Description: Receive standard obstetrical care